B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,241 shares of the company's stock, valued at approximately $830,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at about $27,000. EntryPoint Capital LLC acquired a new position in Axsome Therapeutics during the first quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Axsome Therapeutics in the second quarter valued at approximately $47,000. Russell Investments Group Ltd. boosted its holdings in shares of Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company's stock valued at $63,000 after acquiring an additional 777 shares during the period. Finally, Natixis grew its position in shares of Axsome Therapeutics by 13.6% during the first quarter. Natixis now owns 1,235 shares of the company's stock worth $99,000 after acquiring an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.
Insider Activity
In other news, Director Mark E. Saad sold 11,016 shares of the company's stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares in the company, valued at $913,282.62. This represents a 52.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 22.40% of the company's stock.
Axsome Therapeutics Trading Up 0.5 %
AXSM stock traded up $0.49 during midday trading on Friday, hitting $98.68. The stock had a trading volume of 427,245 shares, compared to its average volume of 557,234. The company's 50-day moving average price is $90.99 and its 200 day moving average price is $85.06. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a market cap of $4.78 billion, a PE ratio of -15.11 and a beta of 1.26. Axsome Therapeutics, Inc. has a 12-month low of $60.28 and a 12-month high of $105.00.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the previous year, the business earned ($1.32) earnings per share. On average, equities research analysts predict that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. UBS Group reduced their target price on shares of Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $130.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued an "overweight" rating and issued a $107.00 target price on shares of Axsome Therapeutics in a report on Monday, September 16th. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Axsome Therapeutics in a report on Thursday, September 5th. Finally, StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $124.93.
Read Our Latest Research Report on Axsome Therapeutics
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
